5-FU is a cheap positive control.

Are you envisaging subcutaneous or orthotopic xenografting into the caecum?

If subcutaneous, your "colon cancer model" is absolutely not relevant and you can use any positive control you want.

If you go with orthotopic xenografts into the caecum, HT-29 tumors respond to irinotecan.

Best regards

Robert

I second irinotecan (60 mg/kg/day, ip, q3dx4) or try gemcitabine (120 mg/kg/day, ip, q3dx4).

Regards,

Andy

Dear Venkata,

I advice you to use the CT26 model (described in the attached document) that you can growth both s.c. and orthotopically.

I think that it is better for use syngeneic colon cancer models in syngeneic mice rather than human cancer cells in SCID mice because you are loosing all the "immuno" part.

The possibility remains that part of your herbal extracts can act, at least partly, through the activation of immuno-responses against the tumor.

Handling in parallel the CT26 model s.c. versus orthotopically will provide you with a clear view about the potential anticancer effects on the primary tumor growth (the s.c. model) versus invasion and metastatic processes (the orthotopic model).

And, CT26 model in syngeneic mice will be by far cheaper than HT29 ones in SCID mice.

The tumor take rates with the CT26 model is 100%M in both s.c. and orthotopic location.

Best regards

Robert

Hope the following links give some information. (If you know these already neglect)

In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201

http://www.surgjournal.com/article/S0039-6060(10)00266-7/pdf

Charles River Immunodeficient Models Xenograft Catalog

http://www.criver.com/files/pdfs/rms/immunodeficient-models-xenograft-data-catalog-volu.aspx

Pharmacology and Antitumor Activity of a Quinolinedione Cdc25 Phosphatase Inhibitor DA3003-1 (NSC 663284)

http://www.iiar-anticancer.org/openAR/journals/index.php/anticancer/article/viewFile/79/77